December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
January 2023 in “Cutaneous and Ocular Toxicology”
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
Cialis and Finasteride could be repurposed to treat aggressive melanoma.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
December 2011 in “The Diabetes Educator” The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
18 citations
,
January 1996 in “Gynecologic and obstetric investigation” The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.
2 citations
,
August 2021 in “Journal of Clinical Psychopharmacology” An 8-year-old girl's eyebrow hair loss was linked to atomoxetine for ADHD but grew back after stopping the medication.
July 2005 in “CME: Your SA Journal of CPD” Botulinum toxin is a safe alternative for treating migraines without common side effects, but should be used after other treatments fail.
Spironolactone may be a better acne treatment for adult women than antibiotics.
July 2023 in “Clinical and Experimental Dermatology” Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
9 citations
,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
35 citations
,
August 2004 in “Epilepsy & behavior” Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
6 citations
,
October 2015 in “Clinical Case Reports” A woman with acromegaly experienced severe hair loss from a drug called Lanreotide Autogel, which improved after stopping the treatment.
9 citations
,
April 2006 in “International Journal of Dermatology” DFMO may help control hair growth and treat cancer.
Baricitinib helps regrow hair in teens with severe alopecia areata.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
34 citations
,
April 1982 in “BMJ” 5 citations
,
July 1987 in “European Journal of Obstetrics & Gynecology and Reproductive Biology” The treatment temporarily improved symptoms of hyperandrogenism in adolescents.
3 citations
,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
21 citations
,
April 2018 in “The Journal of urology/The journal of urology” SER120 nasal spray effectively reduces nighttime urination and is safe for patients.
59 citations
,
January 2011 in “Retina-the Journal of Retinal and Vitreous Diseases” Finasteride may help treat chronic CSC, improving vision.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.